Division of Thermo Fisher Scientific Inc.
Latest From Invitrogen China
James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies. This article is part of Scrip's Biomarkers and Beyond analysis. For more articles, data and multimedia features exploring the role of biomarkers in the future of the pharmaceutical industry, visit scripintelligence.com/biomarkers.
Mr Dino DiCamillo has been appointed executive director of Hycult Biotech Inc, the newly-incorporated US subsidiary of immunology and cell biology biotech company Hycult Biotech BV. Mr DiCamillo is currently president and CEO of Percorso Life Sciences, a consultancy organisation for life science companies focused on the North American market; he has also held presidential and leadership roles at Advanced Research Technologies, Alfa Wassermann Proteomics, Invitrogen and Dynal Biotech Inc.
Gene Logic, part of the Indian genomics services company, Ocimum Biosolutions, has appointed Dr Norrie Russell as president. Dr Russell, who comes with more than 30 years of experience in drug discovery, has previously held leadership positions with NovaRx, Invitrogen, Aviva Biosciences and Lynx Therapeutics. He has also worked for AstraZeneca, where he was global head, biological science and technology.
The buzz around personalised medicine points to a potentially lucrative market for robust biomarkers that will lead the way to more effective targeted therapies. Stefan Fritsch examines the use of genetic and serum- and urine-based biomarkers in the diagnosis of Alzheimer's disease and the factors driving pharma industry interest.
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Bio Asia
- Parent & Subsidiaries
- Thermo Fisher Scientific Inc.
- Senior Management
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.